Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Model-based evaluation of an infant HPV prophylactic vaccination program in Nigeria

Robyn M. Stuart, Umeh Ifeoma Blessing, Christopher Gill, Jamie A. Cohen
doi: https://doi.org/10.64898/2026.09.30.26364434
Robyn M. Stuart
1Bill & Melinda Gates Foundation, Seattle, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: info{at}hpvsim.org
Umeh Ifeoma Blessing
2Department of Clinical Pharmacy, Nnamdi Azikiwe University, Awka, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Gill
1Bill & Melinda Gates Foundation, Seattle, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jamie A. Cohen
1Bill & Melinda Gates Foundation, Seattle, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Nigeria introduced single-dose HPV vaccination for girls aged 9–14 in 2023, reaching approximately 60% aggregate coverage by 2025. While an important achievement, this remains short of the 90% coverage called for under the WHO’s 90-70-90 cervical cancer elimination targets, and further scale-up depends on reaching out-of-school girls. In this study we used a model of HPV transmission in Nigeria to quantify the residual cervical cancer burden under continued adolescent delivery, assess how additional screening scale-up and equity assumptions modify it, and identify the effective coverage requirements for an infant HPV vaccination program to be non-inferior to the existing adolescent strategy.

Methods We used HPVsim, an agent-based microsimulation calibrated to Nigerian sexual behavior, HPV prevalence, and cervical cancer incidence, to project new cervical cancer cases and age-standardized incidence over 2025–2100 under scenarios which vary vaccination delivery mode (status-quo adolescent, WHO 90-70-90 adolescent scale-up, and 60/75/90% infant delivery), screening coverage (opportunistic 15% vs. scaled 70% aggregate), and the degree to which primary school completion correlated with vaccination (odds ratio 1 vs. 5) and with screening (odds ratio 1 vs. 3). Infant delivery scenarios were run at hypothetical effective-vaccine-efficacy-at-exposure values of 50%, 70%, and 95% — scenario inputs bracketing the plausible waning range, not evidence-based estimates of infant vaccine performance (no HPV vaccine trial has enrolled anyone below age 10). Each scenario was run at 50 replicates (10 calibration draws × 5 seeds); reported outcomes are the median across replicates and uncertainty ranges are interquartile (25th–75th percentile).

Results Continuation of Nigeria’s current adolescent program is projected to avert 1.82 million cervical cancer cases (IQR 1.65–1.90 million; 95% UI 1.39–2.02 million) over 2025–2100 (a 53% reduction relative to no vaccination, IQR 51–55%; 95% UI 46–58%), with age-standardized incidence falling from 19.7 to 7.8 per 100,000 by 2100. However, 82% of the near-term (2025–2075) burden is projected to fall on the pre-2015 birth cohort, i.e. women already beyond the vaccination target age, leaving approximately 945,000 residual cases (IQR 905K–1.00M; 95% UI 835K–1.14M) in this cohort. Scaling up screening to WHO targets was estimated to avert a further ∼387K cases (IQR 331–424K; 95% UI 269–515K), roughly 25% of the residual burden; results were about 6–8% better if the scale-up instead reached all women equitably regardless of education. Under a hypothetical scenario of infant vaccination at 90% coverage and 95% effective vaccine efficacy at exposure (matching adolescent-age performance), outcomes were comparable to full WHO adolescent scale-up (49% vs. 54% reduction in vaccine-targetable cohort cancers), but under a hypothetical 50% effective efficacy at Nigeria’s DTP3-anchored 62% coverage the strategy averted only a fraction of these cancers.

Conclusions The near-term cervical cancer burden in Nigeria is dominated by cohorts vaccination cannot reach; scaling screening for them is the more consequential lever over the coming three decades and rests on established evidence. Findings on infant HPV delivery are exploratory and hypothesis-generating: they depend on three unverified empirical prerequisites – infant HPV vaccine immunogenicity in the first months of life, durability of protection across the ∼15–25-year interval to peak HPV exposure, and coverage achievable through Nigeria’s routine childhood immunization platform – and should not be read as a basis for any policy recommendation contingent on infant HPV delivery until those prerequisites are established.

Competing Interest Statement

The authors have declared no competing interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced are available online at https://github.com/hpvsim/hpvsim_pxv_younger

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted October 02, 2026.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Model-based evaluation of an infant HPV prophylactic vaccination program in Nigeria
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Model-based evaluation of an infant HPV prophylactic vaccination program in Nigeria
Robyn M. Stuart, Umeh Ifeoma Blessing, Christopher Gill, Jamie A. Cohen
medRxiv 2026.09.30.26364434; doi: https://doi.org/10.64898/2026.09.30.26364434
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Model-based evaluation of an infant HPV prophylactic vaccination program in Nigeria
Robyn M. Stuart, Umeh Ifeoma Blessing, Christopher Gill, Jamie A. Cohen
medRxiv 2026.09.30.26364434; doi: https://doi.org/10.64898/2026.09.30.26364434

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Policy
Subject Areas
All Articles
  • Addiction Medicine (638)
  • Allergy and Immunology (922)
  • Anesthesia (353)
  • Cardiovascular Medicine (5024)
  • Dentistry and Oral Medicine (496)
  • Dermatology (429)
  • Emergency Medicine (680)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1696)
  • Epidemiology (16286)
  • Forensic Medicine (36)
  • Gastroenterology (1243)
  • Genetic and Genomic Medicine (7298)
  • Geriatric Medicine (754)
  • Health Economics (1095)
  • Health Informatics (5307)
  • Health Policy (1476)
  • Health Systems and Quality Improvement (1837)
  • Hematology (599)
  • HIV/AIDS (1383)
  • Infectious Diseases (except HIV/AIDS) (16508)
  • Intensive Care and Critical Care Medicine (1203)
  • Medical Education (701)
  • Medical Ethics (157)
  • Nephrology (754)
  • Neurology (7620)
  • Nursing (380)
  • Nutrition (1133)
  • Obstetrics and Gynecology (1297)
  • Occupational and Environmental Health (1041)
  • Oncology (3752)
  • Ophthalmology (1097)
  • Orthopedics (411)
  • Otolaryngology (468)
  • Pain Medicine (503)
  • Palliative Medicine (143)
  • Pathology (722)
  • Pediatrics (1864)
  • Pharmacology and Therapeutics (758)
  • Primary Care Research (788)
  • Psychiatry and Clinical Psychology (6156)
  • Public and Global Health (10017)
  • Radiology and Imaging (2543)
  • Rehabilitation Medicine and Physical Therapy (1527)
  • Respiratory Medicine (1274)
  • Rheumatology (663)
  • Sexual and Reproductive Health (806)
  • Sports Medicine (599)
  • Surgery (806)
  • Toxicology (109)
  • Transplantation (320)
  • Urology (309)